Table 2.
Association between various CYP19 genotypes and OS, DFS, or DDFS.
| Genotype | OS | DFS | DDFS | |||
|---|---|---|---|---|---|---|
| Hazard ratio (95% CI) aHR (95% CI) |
P | Hazard ratio (95% CI) aHR (95% CI) |
P | Hazard ratio (95% CI) aHR (95% CI) |
P | |
| CYP19_rs4646 A/A + A/C versus C/C | ||||||
| Total (N = 296) |
1.6 (0.8–3.1) 1.8 (0.9–3.6) |
0.17 0.09 |
1.6 (1.0–2.5) 1.6 (1.0–2.6) |
0.06 0.06 |
1.6 (0.9–2.7) 1.7 (0.9–2.9) |
0.10 0.07 |
| Premenopausal (n = 178) |
2.1 (0.9–4.9) 2.4 (1.0–5.9) |
0.10 0.06 |
1.8 (1.0–3.1) 1.8 (0.9–3.2) |
0.05 0.07 |
2.2 (1.1–4.4) 2.3 (1.1–4.9) |
0.03 0.02 |
| Postmenopausal (n = 118) |
1.0 (0.3–2.9) 1.2 (0.4–3.7) |
0.97 0.81 |
1.3 (0.5–3.0) 1.4 (0.6–3.5) |
0.59 0.42 |
0.9 (0.3–2.2) 1.0 (0.4–2.7) |
0.79 0.99 |
| Premenopausal patients receiving adjuvant chemotherapy (n = 86) | 2.2 (0.6–7.4) 2.8 (0.7–10.7) |
0.22 0.13 |
1.8 (0.8–4.1) 1.7 (0.7–4.1) |
0.15 0.24 |
2.1 (0.8–5.4) 2.2 (0.8–6.3) |
0.12 0.13 |
|
| ||||||
| CYP19_rs1065779 A/A + A/C versus C/C | ||||||
| Total (N = 296) |
1.3 (0.6–2.8) 1.6 (0.7–3.3) |
0.50 0.26 |
2.0 (1.1–3.6) 2.3(1.2–4.2) |
0.02 0.009 |
1.7 (0.9–3.2) 1.9 (1.0–3.7) |
0.87 0.06 |
| Premenopausal (n = 178) |
2.2 (0.8–6.6) 2.6 (0.8–7.8) |
0.15 0.10 |
3.1 (1.4–6.8) 3.5 (1.5–7.9) |
0.006 0.003 |
2.9 (1.1–7.5) 3.2 (1.2–8.6) |
0.03 0.02 |
| Postmenopausal (n = 118) |
0.5 (0.2–1.7) 0.7 (0.2–2.2) |
0.29 0.49 |
1.0 (0.4–2.5) 1.1 (0.4–3.0) |
0.93 0.84 |
0.7 (0.3–2.0) 0.9 (0.3–2.6) |
0.56 0.84 |
| Premenopausal patients receiving adjuvant chemotherapy (n = 86) | 4.1 (0.5–31.8) 7.0 (0.8–62.6) |
0.18 0.08 |
4.9 (1.1–20.7) 6.6 (1.5–29.4) |
0.03 0.01 |
7.0 (0.9–52.0) 13.0 (1.6–104.8) |
0.06 0.02 |
|
| ||||||
| CYP19_(TTTA)n S/S + S/L versus L/L | ||||||
| Total (N = 296) |
2.8 (0.9–9.1) 3.3 (1.0–11.0) |
0.09 0.05 |
2.4 (1.1–5.3) 2.8 (1.3–6.2) |
0.03 0.01 |
2.4 (1.0–6.0) 2.8 (1.1–7.1) |
0.06 0.03 |
| Premenopausal (n = 178) |
6.6 (0.9–48.7) 7.8 (1.0–58.9) |
0.07 0.05 |
3.6 (1.3–10.1) 4.0 (1.4–11.4) |
0.01 0.009 |
5.0 (1.2–20.7) 5.5 (1.3–23.5) |
0.03 0.02 |
| Postmenopausal (n = 118) |
1.0 (0.2–4.5) 1.1 (0.2–5.1) |
0.98 0.93 |
1.2 (0.3–4.0) 1.3 (0.4–4.8) |
0.81 0.64 |
0.9 (0.3–3.1) 1.1 (0.3–4.1) |
0.87 0.86 |
| Premenopausal patients receiving adjuvant chemotherapy (n = 86) | — — |
3.5 (0.8–15.1) 4.0 (0.9–17.9) |
0.09 0.07 |
5.3 (0.7–39.9) 6.3 (0.8–50.8) |
0.10 0.09 |
|
|
| ||||||
| CYP19_rs1870050 A/A versus C/C + A/C | ||||||
| Total (N = 296) |
1.2 (0.6–2.3) 1.2 (0.6–2.4) |
0.62 0.53 |
1.3 (0.8–2.1) 1.4 (0.8–2.2) |
0.31 0.19 |
1.7 (1.0–2.9) 1.8 (1.0–3.1) |
0.06 0.05 |
| Premenopausal (n = 178) |
1.7 (0.7–4.1) 1.9 (0.8–4.7) |
0.22 0.14 |
1.4 (0.8–2.4) 1.5 (0.8–2.8) |
0.28 0.17 |
1.9 (0.9–3.8) 2.1 (1.0–4.3) |
0.07 0.05 |
| Postmenopausal (n = 118) |
0.6 (0.2–1.9) 0.6 (0.2–2.0) |
0.41 0.42 |
1.1 (0.5–2.5) 1.0 (0.4–2.4) |
0.86 0.99 |
1.3 (0.5–3.4) 1.2 (0.5–3.2) |
0.54 0.70 |
| Premenopausal patients receiving adjuvant chemotherapy (n = 86) | 1.8 (0.5–6.9) 2.1 (0.5–8.5) |
0.37 0.28 |
1.1 (0.5–2.6) 1.5 (0.6–3.7) |
0.79 0.40 |
2.7 (0.9–8.1) 3.3 (1.0–10.7) |
0.08 0.05 |